The present invention discloses a method for analysis of drug resistance of tumor cells. The method includes the steps of: (a) providing silicon dioxide nanoparticles, polystyrene-co-polyacrylic acid nanoparticles or metal-organic framework nanoparticles; (b) co-incubating the silicon dioxide nanoparticles, the polystyrene-co-polyacrylic acid nanoparticles or the metal-organic framework nanoparticles with the tumor cells; and (c) detecting endocytosis of the silicon dioxide nanoparticles, the polystyrene-co-polyacrylic acid nanoparticles or the metal-organic framework nanoparticles by the tumor cells. The analysis method of the present invention can analytically identify drug-resistant tumor cells in a clear, intuitive and efficient way. The provided nanoparticles feature simple synthesis processes that take short periods of time, and after they are co-incubated with the tumor cells, a flow cytometer is used for detection. Based on a result of the detection, a degree of drug-resistance of the tumor cells and a proportion of drug-resistant cells therein are determined, making the method simple and efficient.

The particle (1) is suitable for the manufacture of an implantable soft tissue engineering material and comprises: a three-dimensionally warped and branched sheet (2) where (i) the three-dimensionally warped and branched sheet (2) is made from a biocompatible material having a Young's modulus of 1 kPa to 1 GPa; (ii) the three-dimensionally warped and branched sheet (2) has an irregular shape which is encompassed in a virtual three-dimensional envelope (3) having a volume V.sub.E; (iii) the three-dimensionally warped and branched sheet (2) has a mean sheet thickness T; iv) the three-dimensionally warped and branched sheet (2) has a volume V.sub.S; (v) the particle (1) has a Young's modulus of 100 Pa to 15 kPa; and (vi) the particle (1) further comprises a number of protrusions where the three-dimensionally warped and branched sheet (2) reaches the envelope (3); (vii) the particle (1) has a number of interconnected channel-type conduits (5) defined by the branching of the sheet (2) and/or by voids in the sheet (2); and (viii) where the conduits (5) have (a) a mean diameter D.sub.C; and (b) an anisotropicity index of 1.01 to 5.00.

Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.

Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.

The invention relates to a hydrogel matrix comprising a mixture of a covalent peptide-polymer conjugate and an oligosaccharide; wherein the oligosaccharide is a highly negatively charged sulfated oligosaccharide selected from the group consisting of heparin, dextran sulfate, α-cyclodextrin sulfate, β-cyclodextrin sulfate and γ-cyclodextrin sulfate; wherein said polymer comprised in said peptide-polymer conjugate is a linear or multi-arm polyethylene glycol; wherein said peptide comprised in said peptide-polymer conjugate is a peptide, which consists of an amino acid sequence selected from the group consisting of SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO. 18 and SEQ ID NO. 19; and wherein said hydrogel matrix is configured in the form of an oligosaccharide/peptide/polymer system, in which said peptide is chemically conjugated to the polymer such that the hydrogel is obtained by mixing the peptide-polymer conjugate and the oligosaccharide.

Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

The present disclosure is directed to peptide antigens derived from a previously undefined epitope on influenza A virus hemagglutinin and methods for use thereof.

Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.

Disclosed is a fusion polypeptide for inhibiting neovascularization, including a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors, and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide.

Cerium oxide nanoparticles (CNPs) have been proven to exhibit antioxidant properties attributed to its surface oxidation states (Ce4+ to Ce3+ and vice versa) mediated at the oxygen vacancies on the surface of CNPs. Different anions in precursor cerium salts were used to prepare CNPs resulting in disclosed CNPs with varying physicochemical properties such as dispersion stability, hydrodynamic size, and the signature surface chemistry. The antioxidant catalytic activity and oxidation potentials of different CNPs have been significantly altered with the change of anions in the precursor salts. For one, CNPs prepared using precursor salts containing NO.sub.3.sup.− and Cl.sup.− ions exhibited increased antioxidant activity than previously thought possible. The change in oxidation potentials of CNPs with the change in concentration of the nitrate and chloride ions indicates the disclosed CNP's have different surface chemistry and antioxidant properties. These compositions and methods of their synthesis are disclosed.